美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

70.64

+0.84791.21%

成交量：111

成交額：7,823

市值：70.64萬

市盈率：- -

高：70.64

開：70.55

低：70.55

收：69.79

52周最高：85.03

52周最低：56.03

股本：1.00萬

流通股本：1.00萬

量比：0.32

換手率：1.11%

股息：2.08

股息率：2.94%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

創新藥研發加速遇「猴荒」

葛蘭素史克(GSK)股票7月20日收盤下跌3.17%：釋放什麼信號？

TradingKey中文

葛蘭素史克(GSK)股票7月17日盤中下跌3.06%：原因全解讀

TradingKey中文

葛蘭素史克(GSK)跌2.3% 止咳新藥三期臨床失利 20億併購核心管線宣告終止開發

第3次更新-葛蘭素史克因晚期臨床試驗未達預期，停止開發慢性咳嗽藥物

英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作

前沿生物收入調減揭示渠道壓力，經營虧損持續擴大

中國生物製藥早盤升逾5% 與GSK進一步深化獨家戰略合作

GSK將兩款呼吸疾病藥物中國商業化權益授予正大天晴，MNC在華戰略調整加速

中國生物製藥分別與阿斯利康、葛蘭素史克達成重要合作

葛蘭素史克與中國生物製藥深化戰略合作

中國生物製藥：深化與GSK呼吸領域戰略合作

南方财经网

（活力中國調研行）上海生物醫藥產業規模破萬億張江藥谷青年人才成創新藥研發主力

中国新闻网

翰思艾泰-B(03378)：擬與華科前沿交叉研究中心打造新一代AI驅動的創新藥研發範式

美股異動 | 醫藥板塊再獲資金切換葛蘭素史克(GSK.US)漲近5%

葛蘭素史克宣佈要約收購Nuvalent。

摩根大通：生物藥企融資回暖大型藥企行業併購優先級高於獨立IPO

百億美元級收購落定 GSK涉足肺癌精準靶向賽道

经济参考报

數據簡報-全球製藥企業斥資數十億美元以擴大在美國的市場份額

葛蘭素史克佈局肺癌精準治療百億併購Nuvalent擴張腫瘤管線

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/GSKH/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":70.6364,"timestamp":1789588800000,"preClose":69.7885,"halted":0,"volume":111,"delay":0,"changeRate":0.012149566189271809,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盤前交易","change":0.8479,"latestTime":"09-17 06:20:59 EDT","open":70.55,"high":70.6364,"low":70.55,"amount":7823,"amplitude":0.001238,"askPrice":112.31,"askSize":100,"bidPrice":28.4,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":70.6364,"nav":69.73341,"aum":697403.83341,"dividendRate":0.0294,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":70.55,"preClose":70.6364,"latestTime":"16:10 EDT","volume":6,"amount":423.8184,"timestamp":1789589404176,"change":-0.0864,"changeRate":-0.001223,"amplitude":0},"volumeRatio":0.3213665408617991,"impliedVol":0.3521,"impliedVolPercentile":0.9828},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3213665408617991,"shares":10001,"dividePrice":2.0767,"high":70.6364,"amplitude":0.001238,"preClose":69.7885,"low":70.55,"week52Low":56.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":70.6364,"eps":0,"divideRate":0.0294,"volume":111,"delay":0,"ttmEps":0,"open":70.55,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":67.6331,"twentyDayClose":71.1955,"sixtyDayClose":71.6072},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBE","SBIO","GSKH","BBP","XLVI","BIOY","APXH","LFSC","BK4585","WRND","IBB","GDOC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653245757","title":"葛蘭素史克(GSK)股票7月20日收盤下跌3.17%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653245757","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653245757?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 04:16","pubTimestamp":1784578570,"startTime":"0","endTime":"0","summary":"• 受到持续的Zantac诉讼债务以及监管不确定性的影响，GSK股价面临下行压力。\n• 疫苗市场竞争加剧和研发成本上升影响了投资者情绪。\n• 包括威廉指标（Williams %R）在内的技术指标显示该股可能面临潜在的抛售压力。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262042327-market-movers-gsk-20260720","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","GSKH","BK4532","BK4585","LU1829250122.USD","BK4007","GSK.UK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652287844","title":"葛蘭素史克(GSK)股票7月17日盤中下跌3.06%：原因全解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=2652287844","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652287844?lang=zh_tw&edition=fundamental","pubTime":"2026-07-18 02:16","pubTimestamp":1784312169,"startTime":"0","endTime":"0","summary":"• 由于持续进行的善胃得（Zantac）诉讼及潜在的和解负债，葛兰素史克（GSK）股价面临波动。\n• 行业定价压力和机构投资转向导致股价表现走低。\n• 临床管线研究结果的不确定性以及汇率波动影响了该公司的估值和收益。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262038450-market-movers-gsk-20260717","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","LU1829250122.USD","BK4007","GSK.UK","GSKH","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652784289","title":"葛蘭素史克(GSK)跌2.3% 止咳新藥三期臨床失利 20億併購核心管線宣告終止開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2652784289","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652784289?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 22:32","pubTimestamp":1784298747,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药企葛兰素史克 股价承压，报51.56美元，跌2.29%。该药物为高选择性 P2X3 受体拮抗剂，是 2023 年 GSK 斥 20 亿美元全额现金收购 Bellus Health 的核心资产，原本被市场寄予厚望，用于填补难治性慢性咳嗽临床空白。本次 20 亿并购的核心呼吸管线宣告失败，大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期；肠易激综合征赛道市场空间相对有限，难以完全对冲止咳适应症临床失利带来的估值压力。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302703","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","LU1829250122.USD","GSK.UK","KCE","BK4588","BK4532","BK4585","BK4007","CALF","MYLD","XMMO","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652883682","title":"第3次更新-葛蘭素史克因晚期臨床試驗未達預期，停止開發慢性咳嗽藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2652883682","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652883682?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 19:56","pubTimestamp":1784289375,"startTime":"0","endTime":"0","summary":"但也有人认为此次临床试验失败尚在可控范围内。两种剂量均未达到关键次要目标，包括来自“慢性咳嗽日记”的患者报告结果。该公司还计划分享相关数据，以促进对难治性慢性咳嗽这一目前治疗选择有限的疾病的科学理解。全球每年约有1000万患者罹患此病，该病症可能导致患者每天咳嗽超过900次。葛兰素史克于2023年以20亿美元收购Bellus Health公司，从而获得了该药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nL4T43J0WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","GSKH","BK4585","GSK.UK","LU1829250122.USD","GSK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AIPO","ARTY","GDOC","IBB","VTHR","CHAT","BK1191","SG9999015978.USD","PBE","IE00BMCWC346.EUR","IE00BVYPNP33.GBP","QTOC","WRND","IE00BYV24P56.USD","LU2488822045.USD","SG9999004220.SGD","SG9999015952.SGD","BK1593","GSKH","00867","SBIO","IE00BGHQDM52.EUR","BK4585","SG9999015945.SGD","AGIX","SG9999015986.USD","BBP","IE00BVYPNQ40.USD","LFSC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650902698","title":"前沿生物收入調減揭示渠道壓力，經營虧損持續擴大","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902698","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650902698?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 14:18","pubTimestamp":1783664280,"startTime":"0","endTime":"0","summary":"前沿生物近日就上交所2025年年报问询函作出回复，对收入确认调整、经销商库存、研发投入及现金流等问题逐一说明。回复内容揭示了公司在核心产品增长、渠道健康度和费用控制等方面面临的现实压力。艾可宁终端销售能否回暖、渠道库存能否有效消化、费用支出能否得到控制，仍是决定公司未来经营走向的关键变量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-10/doc-inihhzry7114679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","GSK.UK","GSK","SPHQ","GSKH","BK4588","BK4585","LU1829250122.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910625","title":"中國生物製藥早盤升逾5% 與GSK進一步深化獨家戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910625","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650910625?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 10:12","pubTimestamp":1783563120,"startTime":"0","endTime":"0","summary":"　　中国生物制药早盘涨超5%，截至发稿，股价上涨5.39%，现报5.08港元，成交额2.39亿港元。　　7月8日，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克“GSK”于2026年5月达成的独家战略合作，推动两款呼吸领域重磅创新药物惠及更多中国患者。本次合作是集团与GSK战略合作的又一重要进展，标志着双方合作领域从肝病进一步拓展至呼吸系统疾病。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-09/doc-inihench4479325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177","BK4585","LU1829250122.USD","BK4588","BK1191","GSK.UK","BK4532","BK4007","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","GSK","GSKH","BK1515","IE00BZ08YR35.GBP","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096193","title":"GSK將兩款呼吸疾病藥物中國商業化權益授予正大天晴，MNC在華戰略調整加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096193","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649096193?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 16:50","pubTimestamp":1783500612,"startTime":"0","endTime":"0","summary":"而此前，就在今年5月，正大天晴获得GSK乙肝新药Bepirovirsen在中国内地的独家商业化权利。事实上，不只GSK，跨国药企在华战略近年来正在加速调整。一方面，MNC将成熟管线的商业化权益交给国内企业，另一方面，MNC正在加大力度购买中国药企的创新管线。从商业化到研发，内、外资药企的战略调整还在加速。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783500577933587278","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4532","GSK","BK4588","LU1829250122.USD","BK4585","GSK.UK","BK4007","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969580","title":"中國生物製藥分別與阿斯利康、葛蘭素史克達成重要合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969580","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649969580?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 15:55","pubTimestamp":1783497300,"startTime":"0","endTime":"0","summary":"7月8日，中国生物制药有限公司（以下简称“中国生物制药”）公告称，将自主研发的慢性阻塞性肺疾病（COPD）创新药TQC3721（PDE3/4抑制剂）海外权益以总额最高19亿美元授权给阿斯利康，创下近三年中国呼吸领域单产品交易额之最；同日，中国生物制药还宣布将进一步深化与葛兰素史克（GSK）的战略合作，获得GSK两款全球重磅呼吸创新药在中国内地的独家商业化权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798367659.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798367659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2237443895.HKD","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1589","LU0708994859.HKD","BK1191","LU0029864427.USD","LU2089984988.USD","BK4568","IE00BZ08YT58.USD","LU2468319806.SGD","GSK","LU0320765992.SGD","AZNH","LU0889565916.HKD","BK4532","LU0109394709.USD","LU2236285917.USD","LU2462157665.USD","LU2456880835.USD","BK1515","LU2237443978.SGD","LU0289739699.SGD","LU0128525929.USD","BK1521","GSKH","LU2237443382.USD","LU2417539215.USD","BK4585","GSK.UK","LU2237443549.SGD","IE00B3T34201.USD","LU0058720904.USD","IE00BZ08YR35.GBP","LU0310800379.SGD","LU1267930573.SGD","01177","AZN","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2237443622.USD","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649027952","title":"葛蘭素史克與中國生物製藥深化戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649027952","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649027952?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 12:14","pubTimestamp":1783484047,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GSKH","BK4532","01177","HK0000165453.HKD","GSK","BK1191","BK4588","GSK.UK","BK1521","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK4007","BK1589","IE00BZ08YT58.USD","LU1829250122.USD","BK1515","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649072952","title":"中國生物製藥：深化與GSK呼吸領域戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649072952","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649072952?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 12:06","pubTimestamp":1783483560,"startTime":"0","endTime":"0","summary":"【中国生物制药：深化与GSK呼吸领域战略合作】南财智讯7月8日电，中国生物制药（01177.HK）发布自愿公告，宣布其附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克（GSK）于2026年5月达成的独家战略合作，获得GSK两款呼吸领域创新药——氟替美维吸入粉雾剂（商品名：全再乐）和乌美溴铵维兰特罗吸入粉雾剂（商品名：欧乐欣）在中国内地的商业化权益，包括进口、分销、医院准入及推广活动，相关销售收入全额确认为正大天晴营业收入。本次合作系双方继肝病领域后首次拓展至呼吸系统疾病，标志本集团呼吸管线从研发向商业化全面升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154841.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK1515","BK1191","BK4588","GSK.UK","HK0000165453.HKD","BK1521","LU1829250122.USD","IE00BZ08YT58.USD","BK4007","BK1589","GSKH","BK4532","GSK","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"（活力中國調研行）上海生物醫藥產業規模破萬億 張江藥谷青年人才成創新藥研發主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649952006?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’，上海团队有180多名全职员工，90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷，这片曾经的农田已崛起为世界级生物医药创新高地，而活跃其中的青年人才，正成为推动创新药研发的主力军。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WRND","LFSC","GSKH","BK4585","PBE","GDOC","BBP","SBIO","BK4588","XBI","399441","IBB","BK4581","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378)：擬與華科前沿交叉研究中心打造新一代AI驅動的創新藥研發範式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984355?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，为充分发挥产学研结合的优势，加速生物医药研发创新，公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台，以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知，围绕抗体发现与分子设计展开深度合作，共同打造新一代AI驱动的创新药研发范式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","GSKH","BK4585","03378","BK1173","AGIX","QTOC","WRND","PBE","AIPO","BK1161","BBP","IBB","ARTY","BK4588","GDOC","CHAT","VTHR","SBIO","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648703689","title":"美股異動 | 醫藥板塊再獲資金切換 葛蘭素史克(GSK.US)漲近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648703689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648703689?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 23:41","pubTimestamp":1783006872,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，医药板块再获资金切换，葛兰素史克(GSK.US)涨近5%，诺和诺德(NVO.US)、赛诺菲安万特(SNY.US)涨超3%，礼来(LLY.US)涨超2%。分析指出，近期科技股、AI大模型及半导体板块持续调整，以及市场对AI算力投资过热、成本控制及高估值产生严重担忧，相关板块出现高位震荡与获利回吐，资金集中向具有强刚需、受经济周期冲击小的医药板块切换。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","GSK.UK","BK4532","GSK","LU1829250122.USD","09939","159938","BK1574","BK4588","BK4585","BK4007","BK1515","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645281618","title":"葛蘭素史克宣佈要約收購Nuvalent。","url":"https://stock-news.laohu8.com/highlight/detail?id=2645281618","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645281618?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 21:54","pubTimestamp":1782309271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSK.UK","LU1829250122.USD","BK4588","BK4532","BK4139","BK4007","BK4585","GSK","GSKH","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756361","title":"摩根大通：生物藥企融資回暖 大型藥企行業併購優先級高於獨立IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756361","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643756361?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 18:21","pubTimestamp":1781605294,"startTime":"0","endTime":"0","summary":"多数本土生物科技企业采取双轨策略，同步筹备 IPO、对接药企收购资源，不少企业上市落地前完成并购交割。头部药企偏好数十亿美金中型补充式并购，近期葛兰素史克斥资 106 亿美元收购肿瘤药企 Nuvalent，打破中小型并购定价惯例。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301588","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357627491.SGD","IE0009355771.USD","LU0238689110.USD","159839","LU0976567544.SGD","LU1548497426.USD","BK4578","IPOS","LU0211331839.USD","LU0820562030.AUD","LU2505996509.AUD","LU0964807845.USD","LU2592432038.USD","IE00B1XK9C88.USD","PGF","BK4566","IE00BYXW3230.USD","LU1064131342.USD","LU1894683348.USD","IE00BKDWB100.SGD","BK4504","LU0070302665.USD","LU0265550946.USD","JPMO","LU1366192091.USD","LU0310799852.SGD","JPO","IE00B3S45H60.SGD","GSK","JPM","LU0942090050.USD","NVS","GSK.UK","LU2211815571.USD","JPX","GSKH","LU1496350502.SGD","LU0640476718.USD","LU2357305700.SGD","LU1261432733.SGD","LU0251132253.USD","LU0215105999.USD","LU0345769128.USD","LU1629891620.HKD","LU0689472784.USD","LU2237443622.USD","SG9999002224.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0034235303.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643786634","title":"百億美元級收購落定 GSK涉足肺癌精準靶向賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2643786634","media":"经济参考报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643786634?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 04:41","pubTimestamp":1781556073,"startTime":"0","endTime":"0","summary":"上任仅五个月时间，葛兰素史克（以下简称“GSK”）新任首席执行官卢克·米尔斯（LukeMiels）便推动了其掌舵以来最大规模的收购。近日，GSK宣布以106亿美元收购美国临床阶段生物技术公司Nuvalent，从而在肺癌精准治疗领域落下关键一子。这不仅是GSK历史上规模最大的收购案之一，也标志着这家百年药企正试图以资本手段加速弥补肿瘤业务的短板。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606163771957730.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163771957730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","GSK.UK","LU1829250122.USD","BK4007","GSKH","BK4532","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520595","title":"數據簡報-全球製藥企業斥資數十億美元以擴大在美國的市場份額","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520595","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520595?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:41","pubTimestamp":1781527269,"startTime":"0","endTime":"0","summary":"路透6月15日 - 全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔市投资约10亿美元，以加强其眼科护理业务在美国本土的制造能力。默克动物保健部门将投资8.95亿美元，用于扩建其位于堪萨斯州的制造和研发基地，这是该公司截至2028年总额达90亿美元的美国投资计划的一部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4T42N15M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","LU2456880835.USD","LU1244550494.USD","LU1629891620.HKD","LU2168564495.EUR","LU2125909593.SGD","IE00B7SZLL34.SGD","SG9999014567.USD","LU2491049909.HKD","IE00BSNM7G36.USD","LU1829250122.USD","LU1323610961.USD","IE000M9KFDE8.USD","IE000SO60NU8.SGD","IE00B19Z9Z06.USD","LU0385154629.USD","LU1267930490.SGD","LU1116320737.USD","CSL.AU","SG9999014542.SGD","LU2403377893.USD","LU2417539215.USD","BIIB","IE00B19Z3581.USD","LU1929549753.HKD","LU1228905540.USD","GSK.UK","LU1868836757.USD","SG9999001440.SGD","LU1974910355.USD","LU2756315318.SGD","LU0889565916.HKD","LU0792757196.USD","IE00BK4W5L77.USD","LU1074936037.SGD","LU1718418525.SGD","IE00BLSP4239.USD","LU2023250330.USD","LU2108987350.USD","IE00BVYPNV92.GBP","LU0130517989.USD","LU2596442595.SGD","LU0203345920.USD","LU2756315664.SGD","IE000F7OJYX1.SGD","LU1127390331.HKD","IE000MB6IJN5.SGD","IE00B19Z9P08.USD","LU1914381329.SGD","LU0320765059.SGD","LU0345770308.USD","LU1670628061.USD","LU0882574055.USD","LU0321505439.SGD","LU1839511570.USD","LU2237443382.USD","LU2361044865.SGD","LU1162221912.USD","BK7501","ELIS","GSK","LU1941712264.USD","BK4534","LU0256863811.USD","LU2023250504.SGD","LU0787776722.HKD","LU1585245621.USD","SG9999015341.SGD","LU1032466523.USD","BK4566","LU0323591593.USD","LU1267930573.SGD","LU2087621335.USD","LU0053666078.USD","LU0965509283.SGD","IE00B42XCP33.USD","LU1989772923.USD","IE00B3T34201.USD","SGXZ31699556.SGD","LU0661504455.SGD","IE00BVYPNW00.USD","LLYX","LU0354030438.USD","GSKH","LU0456855351.SGD","SGXZ81514606.USD","LU0353189763.USD","LU1280957306.USD","LU1732799900.SGD","LU2471134952.CNY","LU1988902786.USD","LU0234572021.USD","LU2237443895.HKD","IE00BWXC8680.SGD","LU2237443549.SGD","GB00BDT5M118.USD","IE00B1XK9C88.USD","LU1069344957.HKD","LU0882574139.USD","SG9999015358.SGD","LU2750360641.GBP","LU2433249047.HKD","LU2491050154.USD","LU2750360997.AUD","IE0009355771.USD","LU1064131342.USD","GILD","LU0029864427.USD","LU0345769631.USD","LU1778281490.HKD","LU2461242641.AUD","LU1066051498.USD","LLY","SG9999002232.USD","LU0553294199.USD","LU0545562505.USD","BK4504","LU0096364046.USD","LU0094547139.USD","IE00BJJMRY28.SGD","IE00BJJMRZ35.SGD","LU0795875169.SGD","LU1989771016.USD","LU1145028129.USD","LU2746668974.SGD","SG9999015986.USD","BK4139","LU2430703095.HKD","LU1917777945.USD","LU2487616109.SGD","SG9999014906.USD","LU0306807586.USD","LU0640476718.USD","LU1868836914.USD","LU0648001328.SGD","LU0211327993.USD","LU0861579265.USD","IE0002270589.USD","IE00BFSS7M15.SGD","LU2028103732.USD","LU1267930813.SGD","LU0466842654.USD","LU1221951129.SGD","LU0203201768.USD","LU1003077747.HKD","LU0114720955.EUR","LU2125154935.USD","LU0128525929.USD","LU2592432038.USD","LU0689472784.USD","LU0124676726.USD","BK4550","LU0354030511.USD","AZN","LU0203202063.USD","LU0426417589.USD","SG9999001176.SGD","LU1934455863.HKD","LU2265009873.SGD","LU1221951046.USD","LU1059921491.USD","LU1941712348.USD","LU0417517546.SGD","LU0708995401.HKD","LU1061106388.HKD","LU2237443978.SGD","LU2168564222.USD","LU0820561909.HKD","LU0211331839.USD","LU0069063385.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU0203347892.USD","LU1228905037.USD","LU0098860793.USD","BK4516","LU0786609619.USD","LU0949170772.SGD","LU2089984988.USD","LU0432979614.USD","IE00B4JS1V06.HKD","IE0001KFT4U8.USD","IE00BKDWB100.SGD","LU1983299246.USD","LU1037948541.HKD","LU0889566641.SGD","AZNH","LU1043141123.HKD","LU0320765489.SGD","LU0943347566.SGD","LU0321505868.SGD","LU0058720904.USD","LU0265550359.USD","LU1699723380.USD","LU2211815571.USD","LU2471134879.HKD","LU0234570918.USD","LU2505996681.GBP","LU2357627491.SGD","LU1548497426.USD","LU1804176565.USD","LU2505996509.AUD","LU0985481810.HKD","LU1720051108.HKD","BK7511","LU1712237335.SGD","LU0320765992.SGD","LU2324357040.USD","LU0738911758.USD","LU0823434583.USD","LU1093756168.USD","BK4599","SG9999014575.USD","LU2237443465.HKD","LU1121112475.USD","LU0225284248.USD","IE00BFSS8Q28.SGD","LU0471298777.SGD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU1196500208.SGD","BK4588","IE0034235303.USD","LU0980610538.SGD","LU0942090050.USD","LU1430594728.SGD","LU0210536198.USD","LU0109394709.USD","LU2471134523.USD","BK4533","BK4581","LU0266013472.USD","IE0004445239.USD","LU2213496289.HKD","IE00B2B36J28.USD","LU1551013425.SGD","IE00BFXG1179.USD","LU0070217475.USD","LU1934455194.USD","LU0057025933.USD","LU1201861249.SGD","LU1674673428.USD","LU0471298694.HKD","IE00BGHQF631.EUR","LU1244550221.USD","SG9999003800.SGD","LLII","LU1868836591.USD","LU0345770993.USD","LU0820561818.USD","BK7508","IE00BN29S564.USD","LU1267930730.SGD","LU2430703251.USD","BK4578","LU1894683348.USD","LU0708994859.HKD","SG9999015978.USD","LU0079474960.USD","IE00BKVL7J92.USD","LU2237443622.USD","LU0225771236.USD","LU0211328371.USD","LU2063271972.USD","LU1506573853.SGD","LU0868494708.USD","LU0672654240.SGD","LU1035775433.USD","LU2125909247.SGD","BK4585","IE00BDGV0183.EUR","LU2264538146.SGD","BK4559","LU1670627923.USD","LU0859254822.USD","LU2357305700.SGD","IE00B1BXHZ80.USD","SG9999014559.SGD","SG9999011175.SGD","LU1720051017.SGD","LU2237438978.USD","SG9999014898.SGD","LU0289739699.SGD","IE00B894F039.SGD","IE00BJT1NW94.SGD","LU2111349929.HKD","ELIL","LU2491050071.SGD","ABBV","LU2347655156.SGD","LU1623119135.USD","LU0316494557.USD","SG9999018865.SGD","LU1066053197.SGD","LU0158827948.USD","LU2552382058.USD","LU0265550946.USD","LU0965509101.SGD","LU0477156953.USD","LU2023250843.SGD","BK7067","LU2168564149.EUR","LU1496350171.SGD","LU0912757837.SGD","BK4568","LU2125154778.USD","LU2089283258.USD","LU0198837287.USD","LU0289739343.SGD","LU2471134796.USD","IE0002141913.USD","LU2129689514.USD","IE00BKPKM429.USD","SGXZ99366536.SGD","LU2430703178.SGD","IE00B4R5TH58.HKD","BK4592","LU0170899867.USD","LU0965508806.USD","LU0511384066.AUD","LU0823416689.USD","LU1923622614.USD","04332","LU1814569148.SGD","LU0061475181.USD","LU0256863902.USD","LU0823434740.USD","SG9999017495.SGD","LU0130102774.USD","SG9999014914.USD","LU0320765646.SGD","LU1066051811.HKD","LU2133065610.SGD","LU0289961442.SGD","LU0070302665.USD","LU0208291251.USD","LU0225283273.USD","IE00B7KXQ091.USD","IE000WAW04H5.SGD","LU2360032135.SGD","LU1366192091.USD","LU1093756325.SGD","LU2361045086.USD","LU1066051225.USD","LU2129689605.HKD","LU1883839398.USD","LU2242652126.USD","LU0310800379.SGD","LU1057294990.SGD","JNJ","LU0994945656.USD","LU0795875086.SGD","LU0306806265.USD","LU1989772840.SGD","IE00B19Z3B42.SGD","LU2746668461.USD","LLYZ","LU0345769128.USD","LU1032955483.USD","LU1571399168.USD","BK4007","SG9999015952.SGD","BK4583","LU0310799852.SGD","LU2168564065.EUR","LU2023251221.USD","IE0005OL40V9.USD","IE00BK4W5M84.HKD","IE00B3PB1722.GBP","LU0426412945.USD","LU1934455277.USD","MRK","LU1674673691.USD","LU0965509010.AUD","IE00B775H168.HKD","LU0472753341.HKD","LU1244550577.SGD","LU1732800096.USD","LU0097036916.USD","IE00BBT3K403.USD","IE0004445015.USD","LU0122379950.USD","LU0964807845.USD","LU0106261372.USD","IE00BJJMRX11.SGD","LU0545039389.USD","IE000BZT7R73.USD","LU2602419157.SGD","IE00BN8TJ469.HKD","SG9999015945.SGD","LU0238689110.USD","LU1035773651.USD","LU2552382132.HKD","BK4532","SG9999018857.SGD","LU1935042991.SGD","LU0158827781.USD","PFE","LU2360106947.USD","LU0820562030.AUD","LU0868494617.USD","LU1894683264.USD","SGXZ57979304.SGD","LU0689626769.HKD","LU1868837300.USD","LU0006306889.USD","LU0683600562.USD","LU2271345857.HKD","LU2242646821.SGD","LU2089284900.SGD","LU2087625088.SGD","LU2361044949.HKD","LU2168563687.JPY","LU2468319806.SGD","LU1551013342.USD","LU1232071149.USD","LU0109391861.USD","SGXZ51526630.SGD","IE0000B7K699.USD","LU1496350502.SGD","LU1043141396.HKD","IE00BLSP4452.SGD","LU2462157665.USD","LU0210528500.USD","LU0353189680.USD","AMGN","LU0133085943.USD","SG9999001176.USD","LU2112291526.USD","LU2896262040.SGD","LU2552382215.SGD","LU1023059063.AUD","LU1261432733.SGD","LU1868837136.USD","LU2106854487.HKD","LU0985320562.USD","LU1291159041.SGD","SG9999002224.SGD","LU1037948897.HKD","LU1069347547.HKD","LU1116320901.HKD","SG9999014880.SGD","IE00BJLML261.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643271396","title":"葛蘭素史克佈局肺癌精準治療 百億併購Nuvalent擴張腫瘤管線","url":"https://stock-news.laohu8.com/highlight/detail?id=2643271396","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643271396?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 17:08","pubTimestamp":1781514512,"startTime":"0","endTime":"0","summary":"金吾财讯 | 2026 年 6 月 9 日，葛兰素史克  宣布与 Nuvalent 达成全现金收购协议，以每股124美元的价格收购 Nuvalent 全部A类和B类普通股，交易总股本价值约106亿美元，扣除 Nuvalent 账面现金后，GSK净投入估计约94亿美元。这是GSK十余年来规模最大的一笔并购。此次收购契合 GSK 扩张肿瘤管线战略，补充肺癌领域精准治疗能力，预计 2027 年起贡献利润，助力 GSK 应对核心产品专利到期压力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301522","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","GSK","GSKH","BK4588","LU1829250122.USD","BK4007","BK4139","GSK.UK","BK4585","BK4539","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":96,"code":"91000000","status":"200"}]}}